港股異動|復宏漢霖續升10.8% 有望“五連升” 就HLX15與Dr.Reddy’s訂立許可協議+H藥漢斯狀®於歐盟獲批上市
復宏漢霖(2696.HK)盤中升超10.8%,報20.5港元,有望實現“五連升”。該股近五個交易日累計上升超20%。 消息面上,復宏漢霖公吿,公司於2025年2月6日與Dr. Reddy’s Laboratories SA訂立一份許可協議,據此,公司向Dr.Reddy’s授出一項許可,供其於美國及約定的歐洲地區(包括英國、瑞士等42個歐洲國家)內及領域內開發、生產和商業化HLX15(重組抗CD38全人單克隆抗體注射液)的靜脈注射製劑與皮下注射製劑。HLX15是公司自主研發的達雷妥尤單抗生物類似藥,計劃用於治療多發性骨髓瘤。另外,復宏漢霖的抗PD-1單抗H藥漢斯狀®(斯魯利單抗,歐洲商品名:Hetronifly®)正式獲得歐盟委員會批准,聯合卡鉑和依託泊苷用於廣泛期小細胞肺癌成人患者的一線治療,標誌着H藥成為首個且唯一在歐盟獲批上市用於廣泛期小細胞肺癌治療的抗PD-1單抗。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.